Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases

SUMMARY: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor) and ipilimumab (...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Endocrinol Diabetes Metab Case Rep
Main Authors: Lupi, Isabella, Brancatella, Alessandro, Cosottini, Mirco, Viola, Nicola, Lanzolla, Giulia, Sgrò, Daniele, Dalmazi, Giulia Di, Latrofa, Francesco, Caturegli, Patrizio, Marcocci, Claudio
Formato: Artigo
Idioma:Inglês
Publicado: Bioscientifica Ltd 2019
Assuntos:
Insight into Disease Pathogenesis or Mechanism of Therapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790893/
https://ncbi.nlm.nih.gov/pubmed/31610523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-19-0102
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares